Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience (Q38855966)

7 September 2017

title

Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience (English)

1 reference

7 September 2017

0 references

Nabil Abdelrazik

1

1 reference

7 September 2017

publication date

1 December 2007

1 reference

7 September 2017

1 reference

7 September 2017

volume

12

1 reference

7 September 2017

issue

6

1 reference

7 September 2017

page(s)

577-585

1 reference

7 September 2017

cites work

The beta-thalassemias

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

Molecular characterization of beta-thalassemia mutations in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

The Egyptian experience with oral iron chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

Chelation therapy in beta-thalassemia: an optimistic update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

Combined therapy with deferoxamine and deferiprone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

Practical management of iron overload.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

Labile plasma iron in iron overload: redox activity and susceptibility to chelation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

LPI-labile plasma iron in iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701521614

10.1080/10245330701521614

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference